Benefits of early treatment with natalizumab: a real-world study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The impact of early versus later high-efficacy disease-modifying therapy (DMT) in patients with multiple sclerosis (MS) is uncertain. This study reported the association of early versus later natalizumab treatment with real-world clinical outcomes in MS patients.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Mult Scler Relat Disord

Title: Multiple sclerosis and related disorders

Publisher: Elsevier BV

ISSN (Electronic): 2211-0356

ISSN (Print): 2211-0348

Publication date (Electronic): Dec 2022

Volume: 68

Affiliations

[1 ] Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA.

[2 ] Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

[3 ] Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.

[4 ] OhioHealth MS Center, Columbus, OH, USA.

[5 ] Digital Health, Biogen, 225 Binney Street, Cambridge, MA, USA.

[6 ] Global Medical, Biogen, 225 Binney Street, Cambridge, MA, USA, at the time of this study.

[7 ] Research & Development, Biogen, 225 Binney Street, Cambridge, MA, USA.

[8 ] Developmental Sciences, Biogen, 225 Binney Street, Cambridge, MA, USA, at the time of this study.

[9 ] Digital Health, Biogen, 225 Binney Street, Cambridge, MA, USA. Electronic address: james.williams@biogen.com.

Article

Publisher Item ID: S2211-0348(22)00721-0

DOI: 10.1016/j.msard.2022.104216

PubMed ID: 36288658

SO-VID: a7933177-718f-4319-8698-61fea4152cf8

History

Keywords: Natalizumab,Radiological outcomes,Clinical outcomes,Multiple sclerosis

Data availability:

Keywords: Natalizumab, Radiological outcomes, Clinical outcomes, Multiple sclerosis

Comments

Comment on this article

scite_

Cited by 1

Early intensive versus escalation treatment in patients with relapsing–remitting multiple sclerosis in Austria
Authors: Michael Guger, Christian Enzinger, Fritz Leutmezer …

See all cited by